| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
ABO blood group distributions in multiple sclerosis patients from Basque Country; O- as a protective factor
|
Lopetegi, Itziar
|
|
|
5 |
4 |
|
article
|
| 2 |
Activity monitor use among persons with multiple sclerosis: Report on rate, pattern, and association with physical activity levels
|
Silveira, Stephanie L
|
|
|
5 |
4 |
|
article
|
| 3 |
Assessing fatigue in multiple sclerosis: Psychometric properties of the five-item Modified Fatigue Impact Scale (MFIS-5)
|
Meca-Lallana, Virginia
|
|
|
5 |
4 |
|
article
|
| 4 |
Does a modifiable risk factor score predict disability worsening in people with multiple sclerosis?
|
Marck, Claudia H
|
|
|
5 |
4 |
|
article
|
| 5 |
Effectiveness of delayed-release dimethyl fumarate on patient-reported outcomes and clinical measures in patients with relapsing–remitting multiple sclerosis in a real-world clinical setting: PROTEC
|
Berger, T
|
|
|
5 |
4 |
|
article
|
| 6 |
Evaluating the relationship between psychometric intelligence and cognitive functions in paediatric multiple sclerosis
|
Kapanci, Tugba
|
|
|
5 |
4 |
|
article
|
| 7 |
Glatiramer acetate as a clinically and cost-effective treatment of relapsing multiple sclerosis over 10 years of use within the National Health Service: Final results from the UK Risk Sharing Scheme
|
Giovannoni, G
|
|
|
5 |
4 |
|
article
|
| 8 |
Gut microbiota composition during a 12-week intervention with delayed-release dimethyl fumarate in multiple sclerosis – a pilot trial
|
Storm-Larsen, C
|
|
|
5 |
4 |
|
article
|
| 9 |
HDL-cholesterol elevation associated with fingolimod and dimethyl fumarate therapies in multiple sclerosis
|
Blumenfeld Kan, S
|
|
|
5 |
4 |
|
article
|
| 10 |
High serum concentration of vitamin D may protect against multiple sclerosis
|
Biström, Martin
|
|
|
5 |
4 |
|
article
|
| 11 |
Identifying people with multiple sclerosis in the Canadian Primary Care Sentinel Surveillance Network
|
Marrie, Ruth Ann
|
|
|
5 |
4 |
|
article
|
| 12 |
Is multiple sclerosis progression associated with the HLA-DR15 haplotype?
|
Stürner, Klarissa Hanja
|
|
|
5 |
4 |
|
article
|
| 13 |
Machine learning in secondary progressive multiple sclerosis: an improved predictive model for short-term disability progression
|
Law, Marco TK
|
|
|
5 |
4 |
|
article
|
| 14 |
Magnetic resonance spectroscopy evidence for declining gliosis in MS patients treated with ocrelizumab versus interferon beta-1a
|
MacMillan, Erin L
|
|
|
5 |
4 |
|
article
|
| 15 |
PARP-1 deregulation in multiple sclerosis
|
Meira, Maria
|
|
|
5 |
4 |
|
article
|
| 16 |
Patient-reported outcomes in multiple sclerosis: Validation of the Quality of Life in Neurological Disorders (Neuro-QoL™) short forms
|
Medina, Luis D
|
|
|
5 |
4 |
|
article
|
| 17 |
Pregnancy and multiple sclerosis: Risk of unplanned pregnancy and drug exposure in utero
|
Smith, Andrew L
|
|
|
5 |
4 |
|
article
|
| 18 |
Prevalence of multiple sclerosis in Cuenca, Ecuador
|
Correa-Díaz, Edgar Patricio
|
|
|
5 |
4 |
|
article
|
| 19 |
Serum hepcidin levels in multiple sclerosis
|
Bsteh, Gabriel
|
|
|
5 |
4 |
|
article
|
| 20 |
Serum neurofilament light chain concentration in a phase 1/2 trial of autologous mesenchymal stem cell transplantation
|
Baldassari, Laura E
|
|
|
5 |
4 |
|
article
|
| 21 |
Serum neurofilament light levels correlate with change of olfactory function in multiple sclerosis
|
Bsteh, Gabriel
|
|
|
5 |
4 |
|
article
|
| 22 |
Use of healthcare services by patients with multiple sclerosis in France over 2010–2015: a nationwide population-based study using health administrative data
|
Roux, J.
|
|
|
5 |
4 |
|
article
|
| 23 |
Validation of a consumer-grade activity monitor for continuous daily activity monitoring in individuals with multiple sclerosis
|
Block, Valerie J
|
|
|
5 |
4 |
|
article
|
Journal description